ArticleDiabetology international2022

Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial.

Fukumi Yoshikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.